Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally M Hunter

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Copy number aberrations in benign serous ovarian tumors: a case for reclassification?Sally M Hunter, Michael S Anglesio, Raghwa Sharma, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2008
The Drosophila cohesin subunit Rad21 is a trithorax group (trxG) proteinGraham Hallson, Monika Syrzycka, Samantha A Beck, et al.
Genome Medicine|August 11, 2015
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Genome Medicine|January 14, 2017
Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2015
Copy number analysis of ductal carcinoma in situ with and without recurrenceKylie L Gorringe, Sally M Hunter, Jia-Min Pang, et al.
Plos One|April 23, 2014
Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deploymentJason Li, Maria A Doyle, Isaam Saeed, et al.
Oncotarget|October 28, 2015
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genesSally M Hunter, Michael S Anglesio, Georgina L Ryland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driverCatherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION StudyAdrian Minson, Emma Verner, Pratyush Giri, et al.
Gynecologic Oncology|January 7, 2020
Therapeutic options for mucinous ovarian carcinomaKylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Copy number aberrations in benign serous ovarian tumors: a case for reclassification?Sally M Hunter, Michael S Anglesio, Raghwa Sharma, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2008
The Drosophila cohesin subunit Rad21 is a trithorax group (trxG) proteinGraham Hallson, Monika Syrzycka, Samantha A Beck, et al.
Genome Medicine|August 11, 2015
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Genome Medicine|January 14, 2017
Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2015
Copy number analysis of ductal carcinoma in situ with and without recurrenceKylie L Gorringe, Sally M Hunter, Jia-Min Pang, et al.
Plos One|April 23, 2014
Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deploymentJason Li, Maria A Doyle, Isaam Saeed, et al.
Oncotarget|October 28, 2015
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genesSally M Hunter, Michael S Anglesio, Georgina L Ryland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driverCatherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION StudyAdrian Minson, Emma Verner, Pratyush Giri, et al.
Gynecologic Oncology|January 7, 2020
Therapeutic options for mucinous ovarian carcinomaKylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Pageof 3